OKRA.ai to expand EU collaboration with pharmaceutical company Bristol Myers Squibb

OKRA.ai extends its collaboration with the pharmaceutical company Bristol Myers Squibb.

The partnership began in the UK in 2018 and involved using OKRA’s AI technology to bring together multiple sources of data, generate intelligent insights for sales teams and drive automation in the pharmaceutical industry based in New York.

Loubna Bouarfa, CEO and founder of OKRA. Photo: Keith Hepell. (21835209)

The companies expanded their partnership into new markets last year and are expected to expand further into the European Union this year, with a focus on supporting customer engagement.

Loubna Bouarfa, CEO of OKRA.ai and former winner of the CEO of the Year award at the Cambridge Independent Science and Technology Awards, said: “We are very pleased to announce the work with Bristol Myers Squibb. We started in 2018 and continuously validated the benefits and accuracy of our ideas with the team.

“This journey has seen us deploy a fully automated portal that uses large amounts of data, not rules, to support dynamic decision-making across the business organization.

“We continue to educate the industry on what it really means to have an AI brain where automation, data pipelines, accuracy, explainability and transparency are critical to success and Bristol Myers Squibb has fully embraced this. with us.”

OKRA applies AI to all stages of the drug lifecycle, spanning market access, medical and commercial domains.

Read more

OKRA.ai will collaborate with the AWS for Health initiative

OKRA Technologies Unveils ValueScope to Predict New Drug Prices Years Before Launch

Comments are closed.